版本:
中国

BRIEF-Bristol-Myers announces results from extended follow-up data evaluating opdivo

June 16 Bristol-Myers Squibb Co:

* Extended follow-up data evaluating opdivo (nivolumab) shows durable response in adult patients with relapsed or progressed classical hodgkin lymphoma

* Bristol-Myers Squibb- ‍results show overall response rates of 65%/greater with median follow-up of at least 16 months

* Bristol-Myers says as per extended follow-up data evaluating opdivo​, ‍across cohorts, median overall survival not reached, 40% of patients remained on treatment Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐